Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.

Abstract excerpt

Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Body Fluids
• Share to DNA, Neoplasm
• Share to Early Detection of Cancer